A review on newly approved PARP inhibitors: Talazoparib and Olaparib
This project report is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2024.
| 主要作者: | |
|---|---|
| 其他作者: | |
| 格式: | Project report |
| 语言: | English |
| 出版: |
Brac University
2024
|
| 主题: | |
| 在线阅读: | http://hdl.handle.net/10361/24372 |
| id |
10361-24372 |
|---|---|
| record_format |
dspace |
| spelling |
10361-243722024-10-22T21:01:59Z A review on newly approved PARP inhibitors: Talazoparib and Olaparib Karim, Azrin Islam, Farzana School of Pharmacy, Brac University PARP inhibitors Olaparib Talazoparib DNA damage repair DDR signaling pathway Homologous recombination repair Prostate cancer Ovarian cancer Metastatic breast cancer BRCA mutations Cancer--Treatment--Genetic aspects. DNA repair. NAD-ADP-ribosyltransferase--Inhibitors--Therapeutic use. Antineoplastic agents. This project report is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2024. Cataloged from PDF version of project report. Includes bibliographical references (pages 43-46). This review delves into the intricate landscape of Poly ADP-ribose polymerase (PARP) inhibitors, specifically focusing on two notable contenders in cancer therapy – Talazoparib and Olaparib. By targeting the DNA Damage Repair (DDR) signaling system crucial for cancer growth, these inhibitors disrupt essential mechanisms like homologous recombination, base excision repair, and mismatch repair. Talazoparib, a PARP inhibitor, has demonstrated its potential as a breakthrough in metastatic breast cancer with BRCA1/2 mutations, surpassing traditional chemotherapy in efficacy. Through PARP trapping and catalytic inhibition, Talazoparib disrupts repair processes, earning approval for BRCA-mutated breast cancer and homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer.Similarly, Olaparib, another PARP inhibitor, is approved for treating pancreatic, ovarian, breast, and prostate cancers. Its impact on synthetic lethality in cancer cells with BRCA mutations is evident, blocking PARP-mediated repair of single-strand breaks. Clinical trials affirm Olaparib's manageable safety profile and efficacy in treating HER2-negative metastatic breast cancer, prostate cancer, and ovarian cancer. The study concludes that Olaparib and Talazoparib stand as effective therapeutic options across various cancer types and genetic abnormalities. It aims to enlighten medical professionals about the potential of precision medicine in advancing cancer therapy, emphasizing the need for personalized approaches in clinical practice. Azrin Karim B. Pharmacy 2024-10-22T06:34:58Z 2024-10-22T06:34:58Z ©2024 2024-01 Project report ID 20146077 http://hdl.handle.net/10361/24372 en Brac University project reports are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission. 47 pages application/pdf Brac University |
| institution |
Brac University |
| collection |
Institutional Repository |
| language |
English |
| topic |
PARP inhibitors Olaparib Talazoparib DNA damage repair DDR signaling pathway Homologous recombination repair Prostate cancer Ovarian cancer Metastatic breast cancer BRCA mutations Cancer--Treatment--Genetic aspects. DNA repair. NAD-ADP-ribosyltransferase--Inhibitors--Therapeutic use. Antineoplastic agents. |
| spellingShingle |
PARP inhibitors Olaparib Talazoparib DNA damage repair DDR signaling pathway Homologous recombination repair Prostate cancer Ovarian cancer Metastatic breast cancer BRCA mutations Cancer--Treatment--Genetic aspects. DNA repair. NAD-ADP-ribosyltransferase--Inhibitors--Therapeutic use. Antineoplastic agents. Karim, Azrin A review on newly approved PARP inhibitors: Talazoparib and Olaparib |
| description |
This project report is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2024. |
| author2 |
Islam, Farzana |
| author_facet |
Islam, Farzana Karim, Azrin |
| format |
Project report |
| author |
Karim, Azrin |
| author_sort |
Karim, Azrin |
| title |
A review on newly approved PARP inhibitors: Talazoparib and Olaparib |
| title_short |
A review on newly approved PARP inhibitors: Talazoparib and Olaparib |
| title_full |
A review on newly approved PARP inhibitors: Talazoparib and Olaparib |
| title_fullStr |
A review on newly approved PARP inhibitors: Talazoparib and Olaparib |
| title_full_unstemmed |
A review on newly approved PARP inhibitors: Talazoparib and Olaparib |
| title_sort |
review on newly approved parp inhibitors: talazoparib and olaparib |
| publisher |
Brac University |
| publishDate |
2024 |
| url |
http://hdl.handle.net/10361/24372 |
| work_keys_str_mv |
AT karimazrin areviewonnewlyapprovedparpinhibitorstalazoparibandolaparib AT karimazrin reviewonnewlyapprovedparpinhibitorstalazoparibandolaparib |
| _version_ |
1814307831508107264 |